Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

被引：0
|
作者：
Michael Guger
Christian Enzinger
Fritz Leutmezer
Franziska Di Pauli
Jörg Kraus
Stefan Kalcher
Erich Kvas
Thomas Berger
机构：
[1] Kepler University Hospital GmbH,Clinic for Neurology 2, Med Campus III
[2] Johannes Kepler University Linz,Medical Faculty
[3] Medical University of Graz,Department of Neurology
[4] Medical University of Vienna,Department of Neurology
[5] Medical University of Innsbruck,Clinical Department of Neurology
[6] Paracelsus Medical University and Salzburger Landeskliniken,Department of Laboratory Medicine
[7] Heinrich-Heine-University,Department of Neurology, Medical Faculty
[8] Hermesoft,undefined
[9] Data management,undefined
[10] Hermesoft,undefined
[11] Statistics,undefined
来源：
Journal of Neurology | 2021年 / 268卷
关键词：
Disability progression; Long-term; Multiple sclerosis; Natalizumab; Predictor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4303 / 4310
页数：7
相关论文
共 50 条
  • [1] Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry
    Guger, Michael
    Enzinger, Christian
    Leutmezer, Fritz
    Di Pauli, Franziska
    Kraus, Joerg
    Kalcher, Stefan
    Kvas, Erich
    Berger, Thomas
    JOURNAL OF NEUROLOGY, 2021, 268 (11) : 4303 - 4310
  • [2] Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry
    Guger, M.
    Enzinger, C.
    Leutmezer, F.
    Di Pauli, F.
    Kraus, J.
    Kalcher, S.
    Kvas, E.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 629 - 630
  • [3] Long-term treatment with natalizumab in paediatric multiple sclerosis (MS)
    Talab, R.
    Talabova, M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 471 - 472
  • [4] Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
    van Lierop, Zoe Y. G. J.
    Wieske, Luuk
    Koel-Simmelink, Marleen J. A.
    Chatterjee, Madhurima
    Dekker, Iris
    Leurs, Cyra E.
    Willemse, Eline A. J.
    Moraal, Bastiaan
    Barkhof, Frederik
    Eftimov, Filip
    Uitdehaag, Bernhard M. J.
    Killestein, Joep
    Teunissen, Charlotte E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (01) : 102 - 110
  • [5] Predictors of Long-Term Outcome in Multiple Sclerosis Patients Treated with Interferon Beta
    Bermel, Robert A.
    You, Xiaojun
    Foulds, Pamela
    Hyde, Robert
    Simon, Jack H.
    Fisher, Elizabeth
    Rudick, Richard A.
    ANNALS OF NEUROLOGY, 2013, 73 (01) : 95 - 103
  • [6] A new long-term treatment for multiple sclerosis, natalizumab
    Masson, C
    PRESSE MEDICALE, 2003, 32 (39): : 1831 - 1832
  • [7] Serum contactin-1 levels as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
    Van Lierop, Z.
    Wieske, L.
    Willemse, E.
    Dekker, I.
    Leurs, C.
    Koel-Simmelink, M.
    Moraal, B.
    Barkhof, F.
    Uitdehaag, B.
    Killestein, J.
    Teunissen, C.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 190 - 190
  • [8] Long-term outcome in multiple sclerosis patients treated with fingolimod
    Lattanzi, Simona
    Rocchi, Chiara
    Danni, Maura
    Taffi, Ruja
    Cerqua, Raffaella
    Carletti, Stella
    Silvestrini, Mauro
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 45
  • [9] Natalizumab in Multiple Sclerosis: Long-Term Management
    Clerico, Marinella
    Artusi, Carlo Alberto
    Di Liberto, Alessandra
    Rolla, Simona
    Bardina, Valentina
    Barbero, Pierangelo
    De Mercanti, Stefania Federica
    Durelli, Luca
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)
  • [10] Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis
    Prosperini, Luca
    Fanelli, Fulvia
    Pozzilli, Carlo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 364 : 145 - 147
12345